KOD (Kodiak Sciences) Non Operating Income: $-0.14 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KOD Kodiak Sciences Inc KOD
26 GF Score
Price $37.18
! 2 Warning Signs
View Full Analysis

What is Kodiak Sciences Non Operating Income?

Kodiak Sciences KOD +0.27% 26 Non Operating Income is $-0.14 Mil as of Jun. 2026. GuruFocus rates KOD with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Kodiak Sciences's Non Operating Income for the three months ended in Jun. 2026 was $-0.06 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.14 Mil.

Kodiak Sciences Non Operating Income Related Terms

Kodiak Sciences Non Operating Income Historical Data

* Premium members only.

The historical data trend for Kodiak Sciences's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences Non Operating Income Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.19 0.50 0.11 -0.51 -0.10

Kodiak Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.02 -0.04 -0.02 -0.06
KOD
26GF Score
Kodiak Sciences Inc KOD
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-0.14 Mil mean?
Kodiak Sciences (KOD) has a Non Operating Income of $-0.14 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Kodiak Sciences and its competitors.
Is Kodiak Sciences' Non Operating Income too high?
Kodiak Sciences' current Non Operating Income is $-0.14 Mil. Overall, Kodiak Sciences has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' Non Operating Income compare to RAPP and TRVI?
Kodiak Sciences' Non Operating Income of $-0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current Non Operating Income is $-0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (KOD) has a current Non Operating Income of $-0.14 Mil. The current Non Operating Income is $-0.14 Mil. Kodiak Sciences' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Kodiak Sciences (KOD), the current Non Operating Income is $-0.14 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges K27:Germany
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
26GF Score

Get the complete analysis for KOD

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.18
Price